Abstract
Neurophysiological indicators of Alzheimer’s disease include the presence of aggregated amyloid-beta (Aβ) peptide plaques and low levels of the neurotransmitter, acetylcholine, resulting in cognitive impairment. Acetylcholinesterase has been implicated in not only the aggregation of extracellular Aβ peptides through the enzyme’s peripheral anionic site, but also the hydrolysis of acetylcholine at its catalytic active site. Two components in a methanolic extract of black walnuts (Juglians nigra), gallic and ellagic acids, were found to prevent aggregation of Aβ peptides in the presence of acetylcholinesterase and to disaggregate previously formed oligomers. In addition, both compounds inhibited acetylcholinesterase activity, thus retaining higher acetylcholine concentrations. Analysis of phenolic structures related to gallic acid indicated that 1,3,5-trisubstituted phenolic rings conferred these inhibitory effects on acetylcholinesterase, and thus may provide a structural model on which to design dual inhibitors for both acetylcholinesterase catalytic activity and Aβ aggregation and disaggregation.
Keywords: Acetylcholinesterase, aggregation, amyloid-beta, phenol, dual inhibitors, Alzheimer’s disease.
Current Enzyme Inhibition
Title:Trisubstituted Phenolic Compounds as Inhibitors of Acetylcholinesterase and Amyloid Beta Aggregate Formation
Volume: 9 Issue: 1
Author(s): Caroline M. Peckels, Nathan S. Alexander, Gina N. Wilson, Joel M. Karty and Kathryn M. Matera
Affiliation:
Keywords: Acetylcholinesterase, aggregation, amyloid-beta, phenol, dual inhibitors, Alzheimer’s disease.
Abstract: Neurophysiological indicators of Alzheimer’s disease include the presence of aggregated amyloid-beta (Aβ) peptide plaques and low levels of the neurotransmitter, acetylcholine, resulting in cognitive impairment. Acetylcholinesterase has been implicated in not only the aggregation of extracellular Aβ peptides through the enzyme’s peripheral anionic site, but also the hydrolysis of acetylcholine at its catalytic active site. Two components in a methanolic extract of black walnuts (Juglians nigra), gallic and ellagic acids, were found to prevent aggregation of Aβ peptides in the presence of acetylcholinesterase and to disaggregate previously formed oligomers. In addition, both compounds inhibited acetylcholinesterase activity, thus retaining higher acetylcholine concentrations. Analysis of phenolic structures related to gallic acid indicated that 1,3,5-trisubstituted phenolic rings conferred these inhibitory effects on acetylcholinesterase, and thus may provide a structural model on which to design dual inhibitors for both acetylcholinesterase catalytic activity and Aβ aggregation and disaggregation.
Export Options
About this article
Cite this article as:
M. Peckels Caroline, S. Alexander Nathan, N. Wilson Gina, M. Karty Joel and M. Matera Kathryn, Trisubstituted Phenolic Compounds as Inhibitors of Acetylcholinesterase and Amyloid Beta Aggregate Formation, Current Enzyme Inhibition 2013; 9 (1) . https://dx.doi.org/10.2174/1573408011309010009
DOI https://dx.doi.org/10.2174/1573408011309010009 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
On the Physiological Relevance of Muscarinic Acetylcholine Receptors in Alzheimers Disease
Current Medicinal Chemistry Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Neuromuscular Disorders in Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology An Efficient Ionic Liquid Mediated Synthesis, Cholinesterase Inhibitory Activity and Molecular Modeling Study of Novel Piperidone Embedded α ,β-Unsaturated Ketones
Medicinal Chemistry Opiate Addiction Therapies and HIV-1 Tat: Interactive Effects on Glial [Ca<sup>2+</sup>]<sub>i</sub>, Oxyradical and Neuroinflammatory Chemokine Production and Correlative Neurotoxicity
Current HIV Research Raman Spectroscopy-based Metabonomics of HIV-infected Sera Detects Amino Acid and Glutathione Changes
Current Metabolomics N-[3,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide Analogues: Novel Acetyl- and Butyrylcholinesterase Inhibitors
Current Topics in Medicinal Chemistry Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly
Current Alzheimer Research Semantic Dementia: A Mini-Review
Mini-Reviews in Medicinal Chemistry CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
Current Alzheimer Research Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
Current Alzheimer Research Testosterone Replacement Therapy in Older Male Subjective Memory Complainers: Double-Blind Randomized Crossover Placebo-Controlled Clinical Trial of Physiological Assessment and Safety
CNS & Neurological Disorders - Drug Targets Enhancing the Delivery of Anti Retroviral Drug “Saquinavir” Across the Blood Brain Barrier Using Nanoparticles
Current HIV Research Butyrylcholinesterase K and Apolipoprotein ε4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research Towards Alzheimers Disease Vaccination
Mini-Reviews in Medicinal Chemistry Quality of Education and Memory Test Performance in Older Men: The New York University Paragraph Recall Test Normative Data
Current Alzheimer Research Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design